Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection.

Journal of virology

Colman H, Berre-Scoul CL, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.
PMID: 27234346
J Virol. 2016 May 27;90(12):5846. doi: 10.1128/JVI.00507-16. Print 2016 Jun 15.

No abstract available.

Cite
Colman H, Berre-Scoul CL, Hernandez C, et al. Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection. J Virol. 2016;90(12):5846doi: 10.1128/JVI.00507-16.
Colman, H., Berre-Scoul, C. L., Hernandez, C., Pierredon, S., Bihouée, A., Houlgatte, R., Vagner, S., Rosenberg, A. R., & Féray, C. (2016). Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection. Journal of virology, 90(12), 5846. https://doi.org/10.1128/JVI.00507-16
Colman, Hélène, et al. "Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection." Journal of virology vol. 90,12 (2016): 5846. doi: https://doi.org/10.1128/JVI.00507-16
Colman H, Berre-Scoul CL, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C. Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection. J Virol. 2016 May 27;90(12):5846. doi: 10.1128/JVI.00507-16. Print 2016 Jun 15. PMID: 27234346; PMCID: PMC4886769.
Copy Download .nbib Format: NLM
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Dusaud M, Rivoire M, Bayoud Y, Sèbe P, Malavaud B, Daste A, Dariane C, Pignot G, Thoulouzan M, Bosset P, Safsaf A, Rigaud J, Houlgatte A, Durand X.
PMID: 26461704
Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.179. Epub 2014 Oct 30.

No abstract available.

Cite
Dusaud M, Rivoire M, Bayoud Y, et al. Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ? [Not Available]. Prog Urol. 2014;24(13):864doi: 10.1016/j.purol.2014.08.179.
Dusaud, M., Rivoire, M., Bayoud, Y., Sèbe, P., Malavaud, B., Daste, A., Dariane, C., Pignot, G., Thoulouzan, M., Bosset, P., Safsaf, A., Rigaud, J., Houlgatte, A., & Durand, X. (2014). Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ? [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 24(13), 864. https://doi.org/10.1016/j.purol.2014.08.179
Dusaud, M, et al. "Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ?" [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 24,13 (2014): 864. doi: https://doi.org/10.1016/j.purol.2014.08.179
Dusaud M, Rivoire M, Bayoud Y, Sèbe P, Malavaud B, Daste A, Dariane C, Pignot G, Thoulouzan M, Bosset P, Safsaf A, Rigaud J, Houlgatte A, Durand X. Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ? [Not Available]. Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.179. Epub 2014 Oct 30. French. PMID: 26461704.
Copy Download .nbib Format: NLM
Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein.

Neuro-oncology

Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR.
PMID: 34297105
Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177.

BACKGROUND: Metastasis to the brain is a major challenge with poor prognosis. The blood-brain barrier (BBB) is a significant impediment to effective treatment, being intact during the early stages of tumor development and heterogeneously permeable at later stages. Intravenous...

Cite
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, et al. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022;24(1):52-63doi: 10.1093/neuonc/noab177.
Munoz Pinto, M. F., Campbell, S. J., Simoglou Karali, C., Johanssen, V. A., Bristow, C., Cheng, V. W. T., Zarghami, N., Larkin, J. R., Pannell, M., Hearn, A., Chui, C., Brinquis Nunez, B., Bokma, E., Holgate, R., Anthony, D. C., & Sibson, N. R. (2022). Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro-oncology, 24(1), 52-63. https://doi.org/10.1093/neuonc/noab177
Munoz Pinto, Mario F, et al. "Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein." Neuro-oncology vol. 24,1 (2022): 52-63. doi: https://doi.org/10.1093/neuonc/noab177
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177. PMID: 34297105; PMCID: PMC8730757.
Copy Download .nbib Format: NLM
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Bayoud Y, Desfemmes F, Dusaud M, Molimard B, Perinet Marquet C, Houlgatte A, Durand X.
PMID: 26461790
Prog Urol. 2014 Nov;24(13):901. doi: 10.1016/j.purol.2014.09.030. Epub 2014 Oct 30.

No abstract available.

Cite
Bayoud Y, Desfemmes F, Dusaud M, et al. Le défi de la collerette vésicale dans la néphro-urétérectomie pour tumeur du haut appareil : nouvelle technique utilisant la sonde de Fogarty par voie endoscopique. [Not Available]. Prog Urol. 2014;24(13):901doi: 10.1016/j.purol.2014.09.030.
Bayoud, Y., Desfemmes, F., Dusaud, M., Molimard, B., Perinet Marquet, C., Houlgatte, A., & Durand, X. (2014). Le défi de la collerette vésicale dans la néphro-urétérectomie pour tumeur du haut appareil : nouvelle technique utilisant la sonde de Fogarty par voie endoscopique. [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 24(13), 901. https://doi.org/10.1016/j.purol.2014.09.030
Bayoud, Y, et al. "Le défi de la collerette vésicale dans la néphro-urétérectomie pour tumeur du haut appareil : nouvelle technique utilisant la sonde de Fogarty par voie endoscopique." [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 24,13 (2014): 901. doi: https://doi.org/10.1016/j.purol.2014.09.030
Bayoud Y, Desfemmes F, Dusaud M, Molimard B, Perinet Marquet C, Houlgatte A, Durand X. Le défi de la collerette vésicale dans la néphro-urétérectomie pour tumeur du haut appareil : nouvelle technique utilisant la sonde de Fogarty par voie endoscopique. [Not Available]. Prog Urol. 2014 Nov;24(13):901. doi: 10.1016/j.purol.2014.09.030. Epub 2014 Oct 30. French. PMID: 26461790.
Copy Download .nbib Format: NLM
Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein.

Neuro-oncology

Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR.
PMID: 34297105
Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177.

BACKGROUND: Metastasis to the brain is a major challenge with poor prognosis. The blood-brain barrier (BBB) is a significant impediment to effective treatment, being intact during the early stages of tumor development and heterogeneously permeable at later stages. Intravenous...

Cite
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, et al. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022;24(1):52-63doi: 10.1093/neuonc/noab177.
Munoz Pinto, M. F., Campbell, S. J., Simoglou Karali, C., Johanssen, V. A., Bristow, C., Cheng, V. W. T., Zarghami, N., Larkin, J. R., Pannell, M., Hearn, A., Chui, C., Brinquis Nunez, B., Bokma, E., Holgate, R., Anthony, D. C., & Sibson, N. R. (2022). Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro-oncology, 24(1), 52-63. https://doi.org/10.1093/neuonc/noab177
Munoz Pinto, Mario F, et al. "Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein." Neuro-oncology vol. 24,1 (2022): 52-63. doi: https://doi.org/10.1093/neuonc/noab177
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177. PMID: 34297105; PMCID: PMC8730757.
Copy Download .nbib Format: NLM
Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein.

Neuro-oncology

Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR.
PMID: 34297105
Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177.

BACKGROUND: Metastasis to the brain is a major challenge with poor prognosis. The blood-brain barrier (BBB) is a significant impediment to effective treatment, being intact during the early stages of tumor development and heterogeneously permeable at later stages. Intravenous...

Cite
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, et al. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022;24(1):52-63doi: 10.1093/neuonc/noab177.
Munoz Pinto, M. F., Campbell, S. J., Simoglou Karali, C., Johanssen, V. A., Bristow, C., Cheng, V. W. T., Zarghami, N., Larkin, J. R., Pannell, M., Hearn, A., Chui, C., Brinquis Nunez, B., Bokma, E., Holgate, R., Anthony, D. C., & Sibson, N. R. (2022). Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro-oncology, 24(1), 52-63. https://doi.org/10.1093/neuonc/noab177
Munoz Pinto, Mario F, et al. "Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein." Neuro-oncology vol. 24,1 (2022): 52-63. doi: https://doi.org/10.1093/neuonc/noab177
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR. Selective blood-brain barrier permeabilization of brain metastases by a type 1 receptor-selective tumor necrosis factor mutein. Neuro Oncol. 2022 Jan 05;24(1):52-63. doi: 10.1093/neuonc/noab177. PMID: 34297105.
Copy Download .nbib Format: NLM
Computed tomography scans of alcoholics: cerebral atrophy?.

Science (New York, N.Y.)

Carlen PL, Wilkinson DA, Holgate R, Wortzman G.
PMID: 17772428
Science. 1979 Jun 15;204(4398):1238. doi: 10.1126/science.204.4398.1238.

No abstract available.

Cite
Carlen PL, Wilkinson DA, Holgate R, et al. Computed tomography scans of alcoholics: cerebral atrophy?. Science. 1979;204(4398):1238doi: 10.1126/science.204.4398.1238.
Carlen, P. L., Wilkinson, D. A., Holgate, R., & Wortzman, G. (1979). Computed tomography scans of alcoholics: cerebral atrophy?. Science (New York, N.Y.), 204(4398), 1238. https://doi.org/10.1126/science.204.4398.1238
Carlen, P L, et al. "Computed tomography scans of alcoholics: cerebral atrophy?." Science (New York, N.Y.) vol. 204,4398 (1979): 1238. doi: https://doi.org/10.1126/science.204.4398.1238
Carlen PL, Wilkinson DA, Holgate R, Wortzman G. Computed tomography scans of alcoholics: cerebral atrophy?. Science. 1979 Jun 15;204(4398):1238. doi: 10.1126/science.204.4398.1238. PMID: 17772428.
Copy Download .nbib Format: NLM
Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.

European urology focus

Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW.
PMID: 28723432
Eur Urol Focus. 2015 Sep;1(2):185-190. doi: 10.1016/j.euf.2015.06.004. Epub 2015 Jun 23.

BACKGROUND: Risk prediction models for prostate cancer (PCa) have become important tools in reducing unnecessary prostate biopsies. The Prostate Health Index (PHI) may increase the predictive accuracy of such models.OBJECTIVES: To compare two PCa risk calculators (RCs) that include...

Cite
Roobol MJ, Vedder MM, Nieboer D, et al. Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index. Eur Urol Focus. 2015;1(2):185-190doi: 10.1016/j.euf.2015.06.004.
Roobol, M. J., Vedder, M. M., Nieboer, D., Houlgatte, A., Vincendeau, S., Lazzeri, M., Guazzoni, G., Stephan, C., Semjonow, A., Haese, A., Graefen, M., & Steyerberg, E. W. (2015). Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index. European urology focus, 1(2), 185-190. https://doi.org/10.1016/j.euf.2015.06.004
Roobol, Monique J, et al. "Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index." European urology focus vol. 1,2 (2015): 185-190. doi: https://doi.org/10.1016/j.euf.2015.06.004
Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW. Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index. Eur Urol Focus. 2015 Sep;1(2):185-190. doi: 10.1016/j.euf.2015.06.004. Epub 2015 Jun 23. PMID: 28723432.
Copy Download .nbib Format: NLM
Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor.

Oncotarget

Dumont S, Le Pennec S, Donnart A, Teusan R, Steenman M, Chevalier C, Houlgatte R, Savagner F.
PMID: 29662614
Oncotarget. 2018 Mar 23;9(22):15883-15894. doi: 10.18632/oncotarget.24633. eCollection 2018 Mar 23.

The PGC-1 (Peroxisome proliferator-activated receptor Gamma Coactivator-1) family of coactivators (PGC-1α, PGC-1β, and PRC) plays a central role in the transcriptional control of mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) processes. These coactivators integrate mitochondrial energy production into cell metabolism...

Cite
Dumont S, Le Pennec S, Donnart A, et al. Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor. Oncotarget. 2018;9(22):15883-15894doi: 10.18632/oncotarget.24633.
Dumont, S., Le Pennec, S., Donnart, A., Teusan, R., Steenman, M., Chevalier, C., Houlgatte, R., & Savagner, F. (2018). Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor. Oncotarget, 9(22), 15883-15894. https://doi.org/10.18632/oncotarget.24633
Dumont, Solenne, et al. "Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor." Oncotarget vol. 9,22 (2018): 15883-15894. doi: https://doi.org/10.18632/oncotarget.24633
Dumont S, Le Pennec S, Donnart A, Teusan R, Steenman M, Chevalier C, Houlgatte R, Savagner F. Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor. Oncotarget. 2018 Mar 23;9(22):15883-15894. doi: 10.18632/oncotarget.24633. eCollection 2018 Mar 23. PMID: 29662614; PMCID: PMC5882305.
Copy Download .nbib Format: NLM
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Bayoud Y, Fournier G, Rouprêt M, Lugagne P, Dusaud M, Pignot G, Rigaud J, Rivoire M, Safsaf A, Sébe P, Malavaud B, Houlgatte A, Durand X.
PMID: 26461705
Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.178. Epub 2014 Oct 30.

No abstract available.

Cite
Bayoud Y, Fournier G, Rouprêt M, et al. Facteurs prédictifs de procédures chirurgicales complémentaires lors des résections de masses résiduelles rétro-péritonéales des tumeurs germinales post-chimiothérapie. Exploitation de la base française collaborative CCAFU-OGE. [Not Available]. Prog Urol. 2014;24(13):864doi: 10.1016/j.purol.2014.08.178.
Bayoud, Y., Fournier, G., Rouprêt, M., Lugagne, P., Dusaud, M., Pignot, G., Rigaud, J., Rivoire, M., Safsaf, A., Sébe, P., Malavaud, B., Houlgatte, A., & Durand, X. (2014). Facteurs prédictifs de procédures chirurgicales complémentaires lors des résections de masses résiduelles rétro-péritonéales des tumeurs germinales post-chimiothérapie. Exploitation de la base française collaborative CCAFU-OGE. [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 24(13), 864. https://doi.org/10.1016/j.purol.2014.08.178
Bayoud, Y, et al. "Facteurs prédictifs de procédures chirurgicales complémentaires lors des résections de masses résiduelles rétro-péritonéales des tumeurs germinales post-chimiothérapie. Exploitation de la base française collaborative CCAFU-OGE." [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 24,13 (2014): 864. doi: https://doi.org/10.1016/j.purol.2014.08.178
Bayoud Y, Fournier G, Rouprêt M, Lugagne P, Dusaud M, Pignot G, Rigaud J, Rivoire M, Safsaf A, Sébe P, Malavaud B, Houlgatte A, Durand X. Facteurs prédictifs de procédures chirurgicales complémentaires lors des résections de masses résiduelles rétro-péritonéales des tumeurs germinales post-chimiothérapie. Exploitation de la base française collaborative CCAFU-OGE. [Not Available]. Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.178. Epub 2014 Oct 30. French. PMID: 26461705.
Copy Download .nbib Format: NLM
[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M.
PMID: 26461706
Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. Epub 2014 Oct 30.

No abstract available.

Cite
Murez T, Durand X, Rivoire M, et al. Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique. [Not Available]. Prog Urol. 2014;24(13):865doi: 10.1016/j.purol.2014.08.180.
Murez, T., Durand, X., Rivoire, M., Fournier, G., Dariane, C., Rouprêt, M., Lugagne, J., Bosset, P., Pignot, G., Hetet, J., Rigaud, J., Safsaf, R., Pfister, C., Daste, A., Sèbe, P., Malavaud, B., Bossavy, J., Houlgatte, A., Avances, C., Camparo, P., Flechon, A., Culine, S., Iborra, F., Mottet, N., Coloby, P., & Soulié, M. (2014). Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique. [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 24(13), 865. https://doi.org/10.1016/j.purol.2014.08.180
Murez, T, et al. "Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique." [Not Available]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie vol. 24,13 (2014): 865. doi: https://doi.org/10.1016/j.purol.2014.08.180
Murez T, Durand X, Rivoire M, Fournier G, Dariane C, Rouprêt M, Lugagne J, Bosset P, Pignot G, Hetet J, Rigaud J, Safsaf R, Pfister C, Daste A, Sèbe P, Malavaud B, Bossavy J, Houlgatte A, Avances C, Camparo P, Flechon A, Culine S, Iborra F, Mottet N, Coloby P, Soulié M. Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique. [Not Available]. Prog Urol. 2014 Nov;24(13):865. doi: 10.1016/j.purol.2014.08.180. Epub 2014 Oct 30. French. PMID: 26461706.
Copy Download .nbib Format: NLM
Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.

Neuro-oncology

Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR.
PMID: 34297105
Neuro Oncol. 2021 Jul 23; doi: 10.1093/neuonc/noab177. Epub 2021 Jul 23.

BACKGROUND: Metastasis to the brain is a major challenge with poor prognosis. The blood-brain barrier (BBB) is a significant impediment to effective treatment, being intact during the early stages of tumour development and heterogeneously permeable at later stages. Intravenous...

Cite
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, et al. Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab177.
Munoz Pinto, M. F., Campbell, S. J., Simoglou Karali, C., Johanssen, V. A., Bristow, C., Cheng, V. W. T., Zarghami, N., Larkin, J. R., Pannell, M., Hearn, A., Chui, C., Brinquis Nunez, B., Bokma, E., Holgate, R., Anthony, D. C., & Sibson, N. R. (2021). Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab177
Munoz Pinto, Mario F, et al. "Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab177
Munoz Pinto MF, Campbell SJ, Simoglou Karali C, Johanssen VA, Bristow C, Cheng VWT, Zarghami N, Larkin JR, Pannell M, Hearn A, Chui C, Brinquis Nunez B, Bokma E, Holgate R, Anthony DC, Sibson NR. Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein. Neuro Oncol. 2021 Jul 23; doi: 10.1093/neuonc/noab177. Epub 2021 Jul 23. PMID: 34297105.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries